Drug pricing and transparency in Europe and the United States: what is it and how does it work?

References

• Webb E, Richardson E, Vogler S, et al. What are the implications of policies increasing transparency of prices paid for pharmaceuticals? A primer for understanding the policy perspective in light of the empirical evidence Copenhagen (Denmark). World Health Organization; 2022. https://eurohealthobservatory.who.int/publications/i/what-are-the-implications-of-policies-increasing-transparency-of-prices-paid-for-pharmaceuticals
   Google Scholar
• Leite SN, Ribeiro AA, Pontes MA, et al. Drug price transparency initiative: the need for a broader view. Res Social Adm Pharm. 2020 Sep;16(9):1324–1325. PubMed PMID: 32800269; eng. doi: 10.1016/j.sapharm.2020.06.007
   PubMed Web of Science ®Google Scholar
• Barrenho E, Lopert R. Exploring the consequences of greater price transparency on the dynamics of pharmaceutical markets 2022. https://www.oecd-ilibrary.org/content/paper/c9250e17-en
   Google Scholar
• Bentata P, Czech M, Greiner W, et al. The consequences of greater net price transparency for innovative medicines in Europe: searching for a consensus. London: Charles River Associates; 2020. https://www.researchgate.net/publication/347356137_The_consequences_of_greater_Net_Price_Transparency_for_innovative_medicines_in_Europe_Searching_for_a_consensus
   Google Scholar
• Ahmad NS, Makmor-Bakry M, Hatah E. Drug price transparency initiative: a scoping review. Res Social Adm Pharm. 2020 Oct;16(10):1359–1369. PubMed PMID: 31987771; eng. doi: 10.1016/j.sapharm.2020.01.002
   PubMed Web of Science ®Google Scholar
• Shaw B, Mestre-Ferrandiz J. Talkin’ about a resolution: issues in the push for greater transparency of medicine prices. PharmacoEconomics. 2020 Feb;38(2):125–134. PubMed PMID: 31956967; eng. doi: 10.1007/s40273-019-00877-3
   PubMed Web of Science ®Google Scholar
• Rapports d’activité du CEPS France: Ministère de la Santé et de la Prévention. [cited 2023 Sep, 15]. Available from: https://sante.gouv.fr/ministere/acteurs/instances-rattachees/comite-economique-des-produits-de-sante-ceps/article/rapports-d-activite-du-ceps
   Google Scholar
• Simoens S, Huys I. R&D costs of new medicines: a landscape analysis. Front Med. 2021;8:760762. PubMed PMID: 34765624; PubMed Central PMCID: PMCPMC8576181: doi: 10.3389/fmed.2021.760762
   Web of Science ®Google Scholar
• Teramae F, Makino T, Lim Y, et al. Impact of research and development strategy on sustainable growth in multinational pharmaceutical companies. Sustainability. 2020;12(13):5358. PubMed PMID. doi: 10.3390/su12135358
   Web of Science ®Google Scholar
• Muir MA, Alessi SA, King JS. Clarifying costs: can increased price transparency reduce healthcare spending? UC Hastings College of the Law Legal Studies Research Paper Series. 2013.
   Google Scholar
• Angelis A, Polyakov R, Wouters OJ, et al. High drug prices are not justified by industry’s spending on research and development. BMJ. 2023 Feb 15;380:e071710. PubMed PMID: 36792119; eng. doi: 10.1136/bmj-2022-071710
   PubMedGoogle Scholar
• Wouters OJ, Berenbrok LA, He M, et al. Association of Research and Development Investments with treatment costs for new drugs approved from 2009 to 2018. JAMA Netw Open. 2022 Sep 1;5(9):e2218623. PubMed PMID: 36156148; PubMed Central PMCID: PMCPMC9513642. eng. doi: 10.1001/jamanetworkopen.2022.18623
   PubMed Web of Science ®Google Scholar
• Morgan SG, Bathula HS, Moon S. Pricing of pharmaceuticals is becoming a major challenge for health systems. BMJ. 2020 Jan 13;368:l4627. PubMed PMID: 31932289; eng. doi: 10.1136/bmj.l4627
   PubMedGoogle Scholar
• Garattini L, Padula A. Pharmaceutical pricing conundrum: time to get rid of it? Eur J Health Econ. 2018 Nov;19(8):1035–1038. PubMed PMID: 30030646; eng. doi: 10.1007/s10198-018-0995-x
   PubMed Web of Science ®Google Scholar
• Danzon PM. Drug pricing and value in oncology. Recent Results Cancer Res. 2019;213:153–167. PubMed PMID: 30543012; eng. doi: 10.1007/978-3-030-01207-6_10
   PubMedGoogle Scholar
• DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016 May;47:20–33. PubMed PMID: 26928437; eng: doi: 10.1016/j.jhealeco.2016.01.012
   PubMed Web of Science ®Google Scholar
• Garattini L, Finazzi B, Mannucci PM. Pharmaceutical pricing in Europe: time to take the right direction. Intern Emerg Med. 2022 Jun 01;17(4):945–948.
   PubMed Web of Science ®Google Scholar
• Rodwin MA, Gerke S. German pharmaceutical pricing: lessons for the United States. Int J Health Serv. 2022 Jan;52(1):146–158. PubMed PMID: 34668806; eng. doi: 10.1177/00207314211040948
   PubMed Web of Science ®Google Scholar
• Rome BN, Nagar S, Egilman AC, et al. Simulated medicare drug price negotiation under the inflation reduction act of 2022. JAMA Health Forum. 2023 Jan 6;4(1):e225218. PubMed PMID: 36705916; eng. doi: 10.1001/jamahealthforum.2022.5218
   PubMedGoogle Scholar
• Jommi C, Armeni P, Costa F, et al. Implementation of value-based pricing for medicines. Clin Ther. 2020 Jan;42(1):15–24. PubMed PMID: 31882225; eng. doi: 10.1016/j.clinthera.2019.11.006
   PubMed Web of Science ®Google Scholar
• Fontrier AM, Visintin E, Kanavos P. Similarities and differences in health technology assessment systems and implications for coverage decisions: evidence from 32 countries. Pharmaco Economics Open. 2022 May;6(3):315–328. PubMed PMID: 34845671; PubMed Central PMCID: PMCPMC9043057. eng. doi: 10.1007/s41669-021-00311-5
   PubMed Web of Science ®Google Scholar
• Zhang M, Bao Y, Lang Y, et al. What is value in health and healthcare? A systematic literature review of value assessment frameworks. Value Health. 2022 Feb;25(2):302–317. PubMed PMID: 35094803; eng. doi: 10.1016/j.jval.2021.07.005
   PubMed Web of Science ®Google Scholar
• Remuzat C, Urbinati D, Mzoughi O, et al. Overview of external reference pricing systems in europe. J Mark Access Health Policy. 2015;3(1):27675. PubMed PMID: 27123181; PubMed Central PMCID: PMCPMC4802694. doi: 10.3402/jmahp.v3.27675
   Google Scholar
• Kang SY, Bai G, DiStefano MJ, et al. Comparative approaches to drug pricing. Annu Rev Public Health. 2020 Apr 2;41(1): 499–512. PubMed PMID: 31874070; eng. 10.1146/annurev-publhealth-040119-094305
   PubMedGoogle Scholar
• Dabbous M, Chachoua L, Caban A, et al. Managed entry agreements: policy analysis from the European perspective. Value Health. 2020 Apr;23(4):425–433. PubMed PMID: 32327159; eng. doi: 10.1016/j.jval.2019.12.008
   PubMed Web of Science ®Google Scholar
• Toumi M, Jarosławski S. Managed entry agreements and funding for expensive therapies. New York: CRC Press; 2022.
   Google Scholar
• Russo P, Carletto A, Németh G, et al. Medicine price transparency and confidential managed-entry agreements in Europe: findings from the EURIPID survey. Health Policy. 2021 Sep;125(9):1140–1145. PubMed PMID: 34253396; eng. doi: 10.1016/j.healthpol.2021.06.008
   PubMed Web of Science ®Google Scholar
• Lieberman SM, Ginsburg PB. Would price transparency for generic drugs lower costs for payers and patients: Brookings Institute; 2018 [ cited 14]. Available from: https://www.brookings.edu/wp-content/uploads/2017/06/es_20170613_genericdrugpricing.pdf
   Google Scholar
• World Health Organization. Promoting price transparency: WHO guideline on country pharmaceutical pricing policies. A plain language summary 2021. https://apps.who.int/iris/bitstream/handle/10665/341898/9789240024632-eng.pdf
   Google Scholar
• Nagar S, Rand LZ, Kesselheim AS. What should US policymakers learn from international drug pricing transparency strategies? AMA J Ethics. 2022 Nov 1;24(11):E1083–1090. PubMed PMID: 36342492; eng. doi: 10.1001/amajethics.2022.1083
   PubMedGoogle Scholar
• High drug prices: are PBMs the right target?: bipartisan policy center. 2023 [cited 2023 Sep, 15]. Available from: https://bipartisanpolicy.org/blog/are-pbms-the-right-target/
   Google Scholar
• Craven J. Can cost-plus pricing lower the cost of generic drugs for Patients?2022 [cited 2023 Sep 15]. https://www.hmpgloballearningnetwork.com/site/frmc/cover-story/can-cost-plus-pricing-lower-cost-generic-drugs-patients
   Google Scholar
• Waldrop T. Value-based pricing of prescription drugs benefits patients and promotes innovation. American Progress; 2021. https://www.americanprogress.org/article/value-based-pricing-prescription-drugs-benefits-patients-promotes-innovation/
   Google Scholar
• Policy Pillars Of Pharmaceutical Innovation. Switzerland: International federation of pharmaceutical manufacturers & associations (IFPMA). [cit 2023 Sep Mar]. Available from: https://enadmin.rdpac.org/upload/upload_file/1577934105.pdf
   Google Scholar
• Moon S, Jambert E, Childs M, et al. A win-win solution?: a critical analysis of tiered pricing to improve access to medicines in developing countries. Global Health. 2011 Oct 12;7(1):39. doi: 10.1186/1744-8603-7-39
   PubMedGoogle Scholar
• Jommi C, Bertolani A, Armeni P, et al. Pharmaceutical pricing and managed entry agreements: an exploratory study on future perspectives in europe. Health Policy Technol. 2023 Sep 01;12(3):100771. doi: 10.1016/j.hlpt.2023.100771
   Web of Science ®Google Scholar
• Council Directive 89/105/EEC of Relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems. Official Journal Of The European Communities L. 1988 Dec 21; 40 (8): Available from https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:31989L0105
   Google Scholar
• Joosse IR, Tordrup D, Glanville J, et al. Evidence on the effectiveness of policies promoting price transparency - a systematic review. Health Policy. 2023 Aug;134:104681. PubMed PMID: 36372608; PubMed Central PMCID: PMCPMC10357344. eng. doi: 10.1016/j.healthpol.2022.11.002
   PubMed Web of Science ®Google Scholar
• Feldman WB, Rome BN, Avorn J, et al. The future of drug-pricing transparency. N Engl J Med. 2021 Feb 11;384(6):489–491. PubMed PMID: 33440087; eng. doi: 10.1056/NEJMp2033734
   PubMed Web of Science ®Google Scholar
• Vogler S, Paterson KR. Can price transparency contribute to more affordable patient access to medicines? Pharmacoecon Open. 2017 Sep;1(3):145–147. PubMed PMID: 29441499; PubMed Central PMCID: PMCPMC5691843. eng. doi: 10.1007/s41669-017-0028-1
   PubMed Web of Science ®Google Scholar
• Scheetz S, Chin MH. Ethical dimensions of pricing transparency. AMA J Ethics. 2022 Nov 1;24(11):E1031–1033. PubMed PMID: 36661394; eng. doi: 10.1001/amajethics.2022.1031
   PubMedGoogle Scholar
• Dana KN, Hertig JB, Weber RJ. Drug pricing transparency: the new retail revolution. Hosp Pharm. 2017 Feb;52(2):155–159. PubMed PMID: 28321145; PubMed Central PMCID: PMCPMC5345916. eng. doi: 10.1310/hpj5202-155
   PubMedGoogle Scholar
• Monsen CB, Liao JM, Gaster B, et al. The effect of medication cost transparency alerts on prescriber behavior. J Am Med Inform Assoc. 2019 Oct 1;26(10): 920–927. PubMed PMID: 31321427; PubMed Central PMCID: PMCPMC7647180. eng. 10.1093/jamia/ocz025
   PubMed Web of Science ®Google Scholar
• Baseilhac E. De la transparence appliquée à l’accès au marché des médicaments. Journal du Droit de la Santé et de l’Assurance - Maladie (JDSAM). 2022;35(5):67–72. French. doi: 10.3917/jdsam.225.0067
   Google Scholar
• Jason C. Oregon health system implements drug pricing tool into epic EHR. EHRIntelligence. 2019 [cited 2023 Sep 15]. Available from: https://ehrintelligence.com/news/oregon-health-system-implements-drug-pricing-tool-into-epic-ehr
   Google Scholar
• Gupta R, Tsay C, Fogerty RL. Promoting cost transparency to reduce financial harm to patients. AMA J Ethics. 2015 Nov 1;17(11):1073–1078. PubMed PMID: 26595250; eng. doi: 10.1001/journalofethics.2015.17.11.mhst1-1511
   PubMedGoogle Scholar
• Mehta A, Xu T, Bai G, et al. The impact of price transparency for surgical services. Am Surg. 2018 Apr 1;84(4): 604–608. PubMed PMID: 29712614; eng. 10.1177/000313481808400439
   PubMed Web of Science ®Google Scholar
• Acosta A, Ciapponi A, Aaserud M, et al. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database Syst Rev. 2014 Oct 16;2014(10):Cd005979. PubMed PMID: 25318966; PubMed Central PMCID: PMCPMC6703418. eng. doi: 10.1002/14651858.CD005979.pub2
   PubMedGoogle Scholar
• Danzon PM, Towse A. Differential pricing for pharmaceuticals: reconciling access, R&D and patents. Int J Health Care Finance Econ. 2003 Sep;3(3):183–205. PubMed PMID: 14625999; eng. doi: 10.1023/a:1025384819575
   PubMedGoogle Scholar
• Mestre-Ferrandiz J, Towse A, Dellamano R, et al. Multi-indication pricing: pros, cons, and its applicability to the United Kingdom. Value Health. 2016;19(3):A8. doi: 10.1016/j.jval.2016.03.056
   Web of Science ®Google Scholar
• Zhang A, Prang KH, Devlin N, et al. The impact of price transparency on consumers and providers: a scoping review. Health Policy. 2020 Aug;124(8):819–825. PubMed PMID: 32576391; eng. doi: 10.1016/j.healthpol.2020.06.001
   PubMed Web of Science ®Google Scholar
• Kyle MK, Ridley DB. Would greater transparency and uniformity of health care prices benefit poor patients? Health Aff. 2007 Sep;26(5):1384–91. PubMed PMID: 17848449; eng. doi: 10.1377/hlthaff.26.5.1384
   Web of Science ®Google Scholar
• EFPIA. EFPIA response to draft opinion on innovative payment models for high-cost innovative medicines 2017. https://www.efpia.eu/media/288630/final_efpia-response-to-exph-draft-opinion-7_12_2017_wir.pdf
   Google Scholar
• PhRMA responds to HHS DTC rule, launches website providing patients with cost information. WA (DC): Pharmaceutical Research and Manufacturers of America; 2019 [cited 2023 Sep 15]. Available from: https://phrma.org/resource-center/Topics/Access-to-Medicines/PhRMA-Responds-to-HHS-DTC-Rule-Launches-Website-Providing-Patients-with-Cost-Information
   Google Scholar
• World Health Organization. Medicines transparency alliance (MeTA): pathways to transparency, accountability and access: cross-case analysis and review of phase II/Tarin vian … [‎et al]‎. en Vol. 2016, Geneva:World Health Organization; 2016.
   Google Scholar
• Perehudoff K. European governments should align medicines pricing practices with global transparency norms and legal principles. Lancet Reg Health Eur. 2022 May;16:100375. PubMed PMID: 35492963; PubMed Central PMCID: PMCPMC9046441. eng. doi: 10.1016/j.lanepe.2022.100375
   PubMedGoogle Scholar
• World Health Assembly. Improving the transparency of markets for medicines, vaccines, and other health products Geneva: World Health Organization; 2019. https://apps.who.int/iris/handle/10665/329301
   Google Scholar
• Barlas S. Health care price transparency initiatives are all the rage: but burgeoning efforts suffer from myriad shortcomings. P T. 2018 Dec;43(12):744–768. PubMed PMID: 30559585; PubMed Central PMCID: PMCPMC6281149. eng.
   PubMedGoogle Scholar
• Third World Network Info Service on Health Issues. WHO: member states adopt resolution on transparency in medicine pricing 2019. https://www.twn.my/title2/health.info/2019/hi190512.htm
   Google Scholar
• Towards promising opportunities with the new EURIPID collaboration: European Patients Forum; 2019 [Sep 15, 2023]. Available from: https://www.eu-patient.eu/news/latest-epf-news/2019/towards-promising-opportunities-with-the-new-euripid-collaboration/#:~:text=We%20see%20promising%20opportunities%20in,involvement%20in%20this%20crucial%20area
   Google Scholar
• Rahman K. Mitigating corruption risks in covid-19 vaccine rollout. Bergen: U4 anti-corruption resource centre, Chr. Michelsen Institute; 2021.
   Google Scholar
• Rhodes NW, Tom R, Violet B, et al. Jillian. For whose benefit? Transparency in the development and procurement of COVID-19 vaccines. Transparency International Global Health; 2021.
   Google Scholar
• Transparence du prix des médicaments. Question de mme COHEN Laurence (val-de-marne – CRCE): Sénat; 2021 [cited 2023 Sep 15] Question écrite n°23378 – 15e législature. Available from: https://www.senat.fr/questions/base/2021/qSEQ210623378.html
   Google Scholar
• Burton P. Italy takes global lead in pricing transparency by Forcing Pharma to disclose public R&D funding: Pharmaboardroom; 2020. Available from: https://pharmaboardroom.com/articles/italy-takes-global-lead-in-pricing-transparency-by-forcing-pharma-to-disclose-public-rd-funding/
   Google Scholar
• Perehudoff K, Mara K, ‘T hoen E. What is the evidence on legal measures to improve the transparency of markets for medicines, vaccines and other health products (World health Assembly resolution WHA72.8)? Copenhagen: WHO Regional Office for Europe; 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK572572/
   Google Scholar
• Hospital Price Transparency Enforcement Updates: Centers for Medicare & Medicaid Services. 2023 [cited 2023 Sep 15]. Fact sheet. Available from: https://www.cms.gov/newsroom/fact-sheets/hospital-price-transparency-enforcement-updates
   Google Scholar
• Consolidated appropriations ACt, 2021 (CAA): centers for medicare & medicaid services. 2021 [cited 2023 Sep 15]. Available from: https://www.cms.gov/marketplace/about/oversight/other-insurance-protections/consolidated-appropriations-act-2021-caa
   Google Scholar
• Butler J. Drug price transparency laws position states to impact drug prices [Internet]: National Academy for State Health Policy; 2022. Available from: https://nashp.org/drug-price-transparency-laws-position-states-to-impact-drug-prices/
   Google Scholar
• Prescription Drug Pricing Transparency Law Comparison Chart: The National Academy for State Health Policy. 2023 [cited 2023 Sep 15]. Available from: https://nashp.org/prescription-drug-pricing-transparency-law-comparison-chart/
   Google Scholar
• Branigan D. New drug transparency observatory launched in France [Internet]. Health Policy Watch. 2019. Available from: https://healthpolicy-watch.news/new-drug-transparency-observatory-launched-in-france/
   Google Scholar
• Yahia O, Gabour L. Information sur le prix des médicaments remboursables: un pas de plus vers la transparence. DSIH. 2017.
   Google Scholar
• Franzen N, Ziegler A, Romagnoli G, et al. Affordable prices without threatening the Oncological R&D Pipeline-An Economic Experiment on transparency in price negotiations. Cancer Res Commun. 2022 Jan;2(1):49–57. PubMed PMID: 36860697. doi: 10.1158/2767-9764.CRC-21-0031
   PubMedGoogle Scholar
• Riccaboni M, Swoboda T, Van Dyck W. Pharmaceutical net price transparency across european markets: insights from a multi-agent simulation model. Health Policy. 2022 Jun;126(6):534–540. PubMed PMID: 35459584; eng. doi: 10.1016/j.healthpol.2022.03.013
   PubMed Web of Science ®Google Scholar
• Lichtenberg FR. Pharmaceutical companies’ variation of drug prices within and among countries can improve long-term social well-being. Health Aff. 2011 Aug;30(8):1539–44. PubMed PMID: 21821571. doi: 10.1377/hlthaff.2010.0891
   Web of Science ®Google Scholar
• Yadav P. Differential pricing for pharmaceuticals. Review of current knowledge, new findings and ideas for action 2010. https://www.gov.uk/government/publications/differential-pricing-for-pharmaceuticals-review-of-current-knowledge-new-findings-and-ideas-for-action
   Google Scholar
• Vokinger KN, Naci H. Negotiating drug prices in the US-Lessons from Europe. JAMA Health Forum. 2022 Dec 2;3(12):e224801. PubMed PMID: 36547946; eng. doi: 10.1001/jamahealthforum.2022.4801
   PubMedGoogle Scholar
• Sullivan SD. Medicare drug price negotiation in the United States: implications and unanswered questions. Value Health. 2023 Mar;26(3):394–399. PubMed PMID: 36503034; eng. doi: 10.1016/j.jval.2022.11.015
   PubMed Web of Science ®Google Scholar
• Toumi M. Introduction to market access for pharmaceuticals. New York: CRC Press; 2017.
   Google Scholar
• Federal Trade Commission. Price Discrimination: Robinson-Patman Violations. https://www.ftc.gov/advice-guidance/competition-guidance/guide-antitrust-laws/price-discrimination-robinson-patman-violations
   Google Scholar
• Hinsch M, Kaddar M, Schmitt S. Enhancing medicine price transparency through price information mechanisms. Global Health. 10(1): PubMed PMID: 24885767; PubMed Central PMCID: PMCPMC4019947. eng:34. 2014 May 8. 10.1186/1744-8603-10-34
   PubMedGoogle Scholar
• Morgan SG, Vogler S, Wagner AK. Payers’ experiences with confidential pharmaceutical price discounts: a survey of public and statutory health systems in North America, Europe, and Australasia. Health Policy. 2017 Apr;121(4):354–362. PubMed PMID: 28238340; eng. doi: 10.1016/j.healthpol.2017.02.002
   PubMed Web of Science ®Google Scholar
• Ridley DB. Price differentiation and transparency in the global pharmaceutical marketplace. PubMed PMID: 15987224; eng. Pharmacoecon. 2005;23(7):651–8. doi: 10.2165/00019053-200523070-00002
   PubMed Web of Science ®Google Scholar
• Sussex J, Davies C, Marciniak-Nuqui Z, et al. Impacts of increasing requirements for research and development (R&D) cost transparency: literature review. Santa Monica (CA): RAND Corporation; 2023.
   Google Scholar
• Lakdawalla DN. Economics of the pharmaceutical industry. J Econ Lit. 2018;56(2):397–449. doi: 10.1257/jel.20161327
   Web of Science ®Google Scholar
• Paschke A, Dimancesco D, Vian T, et al. Increasing transparency and accountability in national pharmaceutical systems. Bull World Health Organ. 2018 Nov 1;96(11): 782–791. PubMed PMID: 30455533; PubMed Central PMCID: PMCPMC6239016. 10.2471/BLT.17.206516
   PubMed Web of Science ®Google Scholar
• RIZIV/INAMI. Proposed roadmap for the renewal of reimbursement procedures for the purpose of fast and sustainable access to medicines 2023. https://www.inami.fgov.be/nl/themas/kost-terugbetaling/door-ziekenfonds/geneesmiddel-gezondheidsproduct/Paginas/hervorming-terugbetalingsprocedures-geneesmiddelen.aspx
   Google Scholar
• Van de Velden W. Court of audit gets access to secret pharma deals: DE TIJD 3rd March 2020. https://www.tijd.be/politiek-economie/belgie/economie/rekenhof-krijgt-inzage-in-geheime-farmadeals/10212108.html
   Google Scholar
• Strauss M. Pfizer irked after Belgian politician publishes COVID-19 vaccine prices. Reuters. 2020 Sect. Healthcare Pharma.
   Google Scholar